Philipp Haas

Biography

  DEVA’s Capital Markets Board results showed revenue in 2014 was TL$467.9 million, up 11.8% from the same period in 2013 (TL$418.4 million). DEVA’s sales increase was mainly due to increased volumes in DEVA's human pharma and veterinary products business revenue. From 2013 to 2014, human pharma revenue increased by 8.5% (TL$398.9 million to TL$432.7 million), and veterinary business revenue increased by 128.7% (from TL$12.34 million to TL$28.22 million) 

Research Interest

  Within the scope of R&D work, we are developing innovative new forms and products of high added value with our laboratories and production sites equipped with state-ofthe-art technology. In keeping with this, in 2014 we allocated approximately 9% of our turnover to R&D. Consisting of the pre-formulation and pilot production area, synthesis and scaleup laboratories, stability area, analytical development laboratories, biotechnology laboratories, oncolytic and hormone production area, pilot production area, weighing area, raw material packaging material, finished product storehouse, analysis laboratories and CMC documentation archives, DevaArge covers an area of 7.000 square meters